user-generated· earnings
AstraZeneca revises 2030 sales target downward by 2027-03-31
Jefferies analysts noted the trial failure could impact management credibility. If additional setbacks occur or market sentiment deteriorates, AstraZeneca may adjust its $80 billion 2030 sales target to reflect reduced expectations for Wainua and related therapies.
earnings · Prediction Market
- Implied probability (Yes)
- 60%
- Closes
- 2027-03-31
More earnings markets
- Forum AI raises $50M+ in Series B funding by 2027-03-31 — 60% Yes
- Anthropic's compute deal with xAI will underperform revenue targets by Q4 2026 — 70% Yes
- Titleist sells more clubs than Callaway in 2026 — 72% Yes
- Sadi Thermal Machines secures $50M+ funding round by 2027 — 70% Yes
- Lime achieves profitability within 12 months post-IPO — 55% Yes
- SK Hynix ADRs to price at or above midpoint range by July 10 — 75% Yes
- Flexjet stock rises 15% by Q4-2027 on fuel cost advantage — 70% Yes
- Driving instructor revenue drops 15% in Q3 2027 due to test booking changes — 68% Yes
Loading…